NCT06287528View on ClinicalTrials.gov

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

February 23, 2028

Study Completion Date

February 23, 2028

Conditions
Philadelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, AdultRefractory Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia (ALL)Refractory Acute Lymphoid Leukemia in Relapse
Interventions
BIOLOGICAL

19-28z/IL-18 CAR T cells

19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER